Therapeutic Potential of CD1d-Restricted Invariant Natural Killer T Cell–based Treatment for Autoimmune Diseases

REFERENCES

• L.S.K. Walker and A.K. Abbas, The enemy within: Keeping self-reactive T cells at bay in the periphery, Nat. Rev. Immunol., 2: 11–19, 2002.
   PubMed Web of Science ®Google Scholar
• C.C. Goodnow, J. Sprent, B. Fazekas de St. Groth, and C.G. Vinuesa, Cellular and genetic mechanism of self-tolerance and autoimmunity, Nature, 435: 590–597, 2005.
   PubMed Web of Science ®Google Scholar
• B. Kyewski and J. Derbinski, Self-representation is the thymus: An extended view, Nat. Rev. Immunol., 4: 688–698, 2004.
   PubMed Web of Science ®Google Scholar
• M. Kronenberg, Toward an understanding of NKT cell biology: Progress and paradoxes, Annu. Rev. Immunol., 26: 877–900, 2005.
   Google Scholar
• S.B Wilson and T.L. Delovitch, Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity, Nat. Rev. Immunol., 3: 211–222, 2003.
   PubMed Web of Science ®Google Scholar
• J.E. Gumperz, S. Miyake, T. Yamamura, and M.B. Brenner, Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d etramer staining, J. Exp. Med., 195: 625–636, 2002.
   PubMed Web of Science ®Google Scholar
• L.T. Mars, J. Novak, R.S. Liblau, and A. Lehuen, Therapeutic manipulation of iNKT cells in autoimmunity: Modes of action and potential risks, Trends Immunol., 25: 471–476, 2004.
   PubMed Web of Science ®Google Scholar
• L.V. Kaer, α-Galactosylceramide therapy for autoimmune diseases: Prospects and obstacles, Nat. Rev. Immunol., 5: 31–42, 2005.
   PubMed Web of Science ®Google Scholar
• K.O.A. Yu and S.A. Porcelli, The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy, Immmunol. Lett., 100: 42–55, 2005.
   Google Scholar
• S.L. Cardell, The natural killer T lymphocyte: A player in the complex regulation of autoimmune diabetes in non-obese diabetic mice, Clin. Exp. Immmunol., 143: 197–202, 2005.
   Google Scholar
• O. Akbari, P. Stock, E. Meyer, M. Kronenberg, S. Sidobre, T. Nakayama, M. Taniguchi, M.J. Grusby, R.H. Dekruyff, and D.T. Umetsu, Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity, Nat. Med., 9: 582–588, 2003.
   PubMed Web of Science ®Google Scholar
• M. Lisbonne, S. Diem, A. de Castro Keller, J. Lefort, L.M. Araujo, P. Hachem, J.M. Fourneau, S. Sidobre, M. Kronenberg, M. Taniguchi, P. Van Endert M. Dy, P. Askenase, M. Russo, B.B. Vargafig, A. Herbelin, and M.C. Leite-de-Morase, Invariant V alpha 14 NKT cells are required for allergen-induced airway inflammation and hyperactivity in an experimental asthma model, J. Immunol., 171: 1637–1641, 2003.
   PubMed Web of Science ®Google Scholar
• O. Akbari, J.L. Faul, E.G. Hoyte, G.J. Berry, J. Wahlstrom, M. Kronenberg, R.H. DeKruyff, and D.T. Umetsu, CD4 + invariant T-cell-receptor + natural killer T cells in bronchial asthma, N. Engl. J. Med., 354: 1117–1129, 2006.
   PubMed Web of Science ®Google Scholar
• Y. Nakai, K. Iwabuchi, S. Fujii, N. Ishimori, N. Dashtsoodol, K. Watano, T. Mishima, C. Iwabuchi, S. Tanaka, J.S. Bezbradica, T. Nakayama, M. Taniguchi, S. Miyake, T. Yamamura, A. Kitabatake, S. Joyce, L. Van Kaer, and K. Onoe, Natural killer T cells accelerate atherogenesis in mice, Blood, 104: 2051–2059, 2004.
   PubMed Web of Science ®Google Scholar
• E. Tupin, A. Nicoletti, R. Elhage, M. Rudling, H.G. Ljunggren, G.K. Hansson, and G.P. Berne, CD1d-dependent activation of NKT cells aggravates atherosclerosis, J. Exp. Med., 199: 417–422, 2004.
   PubMed Web of Science ®Google Scholar
• A. Chiba, S. Oki, K. Miyamoto, H. Hashimoto, T. Yamamura, and S. Miyake, Suppression of collagen-induced arthritis by natural killer activation with OCH, a sphingosine-truncated analog of α-galactosylceramide, Arthritis Rheum., 50: 305–313, 2004.
   PubMed Web of Science ®Google Scholar
• A. Chiba, S. Kaieda, S. Oki, T. Yamamura, and S. Miyake, The involvement of Vα14 natural killer T cells in the pathogenesis of murine models of arthritis, Arthritis Rheum., 52: 1941–1948, 2005.
   PubMedGoogle Scholar
• Y. Ohnishi, A. Tsutsumi, D. Goto, S. Itoh, I. Matsumoto, M. Taniguchi, and T. Sumida, TCR Vα14 + natural killer T cell function and effector T cells in mice with collagen-induced arthritis, Clin. Exp. Immunol., 141: 47–53, 2005.
   Google Scholar
• H.Y. Kim, H.J. Kim, H.S. Min, E.S. Park, S.H. Park, and D.H. Chung, NKT cells promote antibody-induced arthritis by suppressing transforming growth β1 production, J Exp. Med., 201: 41–47, 2005.
   Google Scholar
• J. Mattner, K.L. Debord, N. Ismail, R.D. Goff, C. Cantu III, D. Zhou, P. Saint-Mezard, V. Wang, Y. Gao, N. Yin, K. Hoebe, O. Schneewind, D. Walker, B. Beuter, L. Teyton, P.B. Savage, and A. Bendelac, Exoenous and endogenous glycolipid antigens activate NKT cells during microbial infections, Nature, 434: 525–529, 2005.
   PubMed Web of Science ®Google Scholar
• Y. Kinjo, D. Wu, G. Kim, G.W. Xing, M.A. Poles, D.D. Ho, M. Suji, K. Kawahara, C.H. Won, and M. Kronenberg, Recognition of bacterial glycosphingolipids by natural killer T cells, Nature, 434: 520–525, 2005.
   PubMed Web of Science ®Google Scholar
• K. Fischer, E. Scotet, M. Niemeyer, H. Koebernick, J. Zerrahn, S. Maillet, R. Hurwitz, M. Kursar, M. Bonneville, S.H. Kaufmann, and U.E. Schaible, Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricgted T cells, Proc. Natl. Acad. Sci. U. S. A., 101: 10685–10690, 2004.
   PubMed Web of Science ®Google Scholar
• H.J. van Der Vliet, N. Nishi, T.D. de Gruijil, B.M. von Blomberg, A.J. van den Eertwegh, H.M. Pinedo, G. Giaccone, and R.J. Scheer, Human natural killer T cells acquire a memory-activated phenotype before birth, Blood, 95: 2440–2442, 2000.
   PubMed Web of Science ®Google Scholar
• A. D'Andrea, D. Goux, C. De Lalla, Y. Koezuka, D. Montagna, A. Moretta, P. Dellabona, G. Casorati, and S. Abrignani, Neonatal invariant Vα24+ NKT lymphocytes are activated memory cells, Eur. J. Immunol., 30: 1544–1550, 2000.
   PubMedGoogle Scholar
• S.H. Park, K. Benlagha, D. Lee, E. Balish, and A. Bendelac, Unaltered phenotype, tissue distribution and function of Vα14 (+) NKT cells in germ-free mice, Eur. J. Immunol., 30: 620–625, 2000.
   PubMedGoogle Scholar
• S. Joyce, A.S. Woods, J.W. Yewdell, J.R. Bennink, A.D. De Lilva, A. Boesteanu, S.P. Balk, R.J. Cotter, and R.R. Brutkiewicz, Ntural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol, Science, 279: 1541–1544, 1998.
   PubMed Web of Science ®Google Scholar
• J.E. Gumperz, C. Roy, A. Makowska, D. Lum, M. Sugita, T. Podrebarac, Y. Koezuka, S.A. Porcelli, S. Cardell, M.B. Brenner, S.M. Behar, Murine CD1d-restricted T cell recognition of cellular lipids, Immunity, 12: 211–221, 2000.
   PubMed Web of Science ®Google Scholar
• D. Zhou, J. Mattner, Cantu III, N. Schrantz, N. Yin, Y. Gao, Y. Sagiv, K. Hudspeth, Y.P. Wu, T. Yamashita, S. Teneberg, D. Wang, R.L. Proia, S.B. Levery, P.B. Savage, L. Teyton, and A. Bendelac, Lysosomal glycosphingolipid recognition by NKT cells, Science, 306: 1786–1789, 2004.
   PubMed Web of Science ®Google Scholar
• T. Kawano, J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, and H. Koseki, Taniguchi M CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides, Science, 278: 1626–1629, 1997.
   PubMed Web of Science ®Google Scholar
• L. Brossay, M. Chioda, N. Burdin, Y. Koezuka, G. Casorati, P. Dellabona, and M. Kronenberg, CD1d-mediated recognition of an a-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution, J. Exp. Med., 188: 1521–1528, 1998.
   PubMed Web of Science ®Google Scholar
• F.M. Spada, Y. Koezuka, and S.A. Porcelli, CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells, J. Exp. Med., 188: 1529–1534, 1998.
   PubMed Web of Science ®Google Scholar
• T. Yoshimoto and W.E. Paul, CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3, J. Exp. Med., 179: 1285–1295, 1994.
   PubMed Web of Science ®Google Scholar
• J.L. Matsuda, L. Gapin, J.L. Baron, S. Sidbre, D.B. Stetson, M. Mohrs, R.M. Locksley, and M. Kronenerg, Mouse Vα14i natural killer T cells are resistant to cytokine polarization in vivo, Proc. Natl. Acad. Sci. U. S. A., 100: 8395–8400, 2003.
   PubMed Web of Science ®Google Scholar
• D.B. Stetson, M. Mohrs, R.L. Reinhardt, J.L. Baron, Z.E. Wang, L. Gapin, M. Kronenberg, and R.M. Locksley, Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function, J. Exp. Med., 198: 1069–1076, 2003.
   PubMed Web of Science ®Google Scholar
• J.T. Michael, A.S. Weinmann, J.L. Matsuda, R. Salomon, P.J. Farnham, C.A. Biron, L. Gapin, and L.H. Glimcher, T-bet regulates the terminal maturation and homeostasis of NK and Vα14 NKT cells, Immunity, 20: 477–494, 2004.
   Google Scholar
• N.Y. Crowe, A.P. Uldrich, K. Kyparissoudis, K.J. Hammond, Y. Hayakawa, S. Sidobre, R. Keating, M. Kroneneberg, M.J. Smyth, and D.I. Godfrey, Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells, J. Immunol., 171: 4020–4027, 2003.
   PubMed Web of Science ®Google Scholar
• M.T. Wilson, C. Johansson, D. Olivares-Villagomez, A.K. Singh, A.K. Stanic, C.R. Wang, S. Joyce, M.J. Wick, and L. Van Kaer, Te response of natual killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion, Proc. Natl. Acad. Sci. U. S. A., 100: 10913–10918, 2003.
   PubMed Web of Science ®Google Scholar
• M. Harada, K. Seino, H. Wakao, S. Sakata, Y. Ishizuka, T. Ito, S. Kojo, T. Nakayama, and M. Taniguchi Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation, Int. Immunol., 16: 241–247, 2004.
   PubMed Web of Science ®Google Scholar
• C. Carnaud, D. Lee, O. Donnars, S.H. Park, A. Beavis, Y. Koeauka, and A. Bendelac, Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cell, J. Immunol., 163: 4647–4650, 1999.
   PubMed Web of Science ®Google Scholar
• H. Kitamura, K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, M. Taniguchi, and T. Nishimura, The natural killer T (NKT) cell ligand α-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells, J. Exp. Med., 189: 1121–1128, 1999.
   PubMed Web of Science ®Google Scholar
• S. Fujii, K. Shimizu, C. Smith, L. Bonifaz, and R.M. Steinman, Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered proten, J. Exp. Med., 198: 267–279, 2003.
   PubMed Web of Science ®Google Scholar
• J.D. Wesley, S.H. Robbins, S. Sidobre, M. Kronenberg, S. Terrizzi, and L. Brossay, Cutting edge: IFN-γ signaling to macrophages is required for optimal Vα14i NK T/NK cell cross-talk, J. Immunol., 174: 3864–3868, 2005.
   PubMedGoogle Scholar
• H. Kitamura, A. Ohta, M. Sekimoto, M. Sato, K. Iwakabe, M. Nakui, T. Yahata H.K. Meng, T. Koda, S. Nishimura, T. Kawano, M. Taniguchi, and T. Nishijura, α-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells, Cell. Immmunol., 199: 37–42, 2000.
   PubMed Web of Science ®Google Scholar
• K. Miyamoto, S. Miyake, and T.A. Yamamura, Synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells, Nature, 413: 531–534, 2001.
   PubMed Web of Science ®Google Scholar
• S. Oki, A. Chiba, T. Yamamura, and S. Miyake, The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells, J. Clin. Invest., 113: 1631–1640, 2004.
   PubMed Web of Science ®Google Scholar
• M. Koch, V.S. Stronge, D. Shepherd, S.D. Gadola, B. Mathew, G. Ritter, A.R. Fersht, G.S. Besra, R.R. Schmidt, E.Y. Jones, and V. Cerundolo, The crystal structure of human CD1d with and without alpha-galactosylceramide, Nat. Immunol., 6: 819–826, 2005.
   PubMed Web of Science ®Google Scholar
• M.A. Aronica, A. Mora, D.B. Mitchell, P.W. Finn, J.E. Johnson, J.R. Sheller, and M.R. Boothby, Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo, J. Immunol., 163: 5116–5124, 1999.
   PubMed Web of Science ®Google Scholar
• B.A. Hilliard, N. Mason, L. Xu, J. Sun, S.E. Lamhamedi-Cherradi, H.C. Liou, C. Hunter, and Y.H. Chen, Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation, J. Clin. Invest., 110: 843–850, 2002.
   PubMed Web of Science ®Google Scholar
• W. Wang, W.F. Tam, C.C. Hughes, S. Rath, and R. Sen, Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation, Immunity, 6: 165–174, 1997.
   PubMed Web of Science ®Google Scholar
• O. Rott, E. Cash, and B. Fleischer, Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats, Eur. J. Immunol., 23: 1745–1751, 1993.
   PubMed Web of Science ®Google Scholar
• S. Feske, R. Draeger, H.H. Peter, K. Eichmann, and A. Rao, The duration of nuclear residence of NFAT determines the pattern of cytokine expression in human SCID T cells, J. Immunol., 165: 297–305, 2000.
   PubMed Web of Science ®Google Scholar
• C.M. Porter and N.A. Clipstone, Sustained NFAT signaling promotes a Th1-like pattern of gene expression in primary murine CD4 + T cells, J. Immunol., 168: 4936–4945, 2002.
   PubMed Web of Science ®Google Scholar
• S. Oki, C. Tomi, T. Yamamura, and S. Miyake, Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo, Int. Immunol., 17: 1619–1629, 2005.
   PubMedGoogle Scholar
• V. Parekh, A.K. Singh, M.T. Wilson, D. Olivares-Villagomez, J.S. Gezbradica, H. Inazawa, H. Ehara, T. Sakai, I. Serizawa, L. Wu, C.R. Wang, S. Joyce, and L. Van Kaer, Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids, J. Immunol., 173: 3693–3706, 2004.
   PubMed Web of Science ®Google Scholar
• J.R. Ortaldo, H.A. Youg, R.T. Winkler-Pickett J. R. EW Bere, W.J. Murphy, and R.H. Wiltrout, Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides, J. Immunol., 172: 943–953, 2004.
   PubMed Web of Science ®Google Scholar
• E. Pal, T. Tabira, T. Kawano, M. Taniguchi, S. Miyake, and T. Yamamura, Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα 14 NK T cells, J. Immunol., 166: 662–668, 2001.
   PubMed Web of Science ®Google Scholar
• H. Kitamura, K. Iwakabe, T. Yahata, S. Nishimura, A. Ohta, Y. Ohmi, M. Sato, K. Takeda, K. Okumura, L. Van Kaer, T. Kawano, M. Taniguchi, and T. Nishimura, The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells, J. Exp. Med., 189: 1121–1128, 1999.
   PubMed Web of Science ®Google Scholar
• O. Schulz, A.D. Edwards, M. Schito, J. Aliberti, S. Manickasingham, A. Sher, and C. Reis e Sousa, CD40 treggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal, Immunity, 13: 453–462, 2000.
   PubMed Web of Science ®Google Scholar
• P.L. Vieira, E.C. de Jong, E.A. Wierenga, M.L. Kapsenberg, and P. Kalinski, Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction, J. Immunol., 164: 4507–4512, 2000.
   PubMed Web of Science ®Google Scholar
• M.P. Hayes, F.J. Murph, and P.R. Burd, Interferon-gamma-dependent inducible expression of the human interleukin-12 p35 gene in monocytes initiates from a TATA-containing promoter distinct from the CpG-rich promoter acive in Epstein-Barr virus-transformed lymphoblastoid cells, Blood, 91: 4645–4651, 1998.
   PubMedGoogle Scholar
• X. Ma, J.M. Chow, G. Gri, G. Cara, F. Geroosa, S.F. Wolf, R. Dzialo, and G. Trnchier, The interleukin 12p40 gene promoter is primed by interferon gamma in monocytiv cells, J. Exp. Med., 183: 147–157, 1996.
   PubMed Web of Science ®Google Scholar
• R.D. Goff, Y. Gao, J. Mattner, D. Zhou, N. Yin, Cantu, CIII, L. Teyton, A. Bendelac, and P.B. Savage, Effects of lipid chain length in α-galactosylceramides on cytokine release by natural killer T cells, J. Am. Chem. Soc., 126: 13602–13603, 2004.
   PubMed Web of Science ®Google Scholar
• K.O. Yu, J.S. Im, A. Molano, Y. Dutronc, P.A. Illarionov, C. Forstier, N. Fujiwara, I. Aias, S. Miyake, T. Yamamura, Y.T. Chang, G.S. Besra, and S.A. Porcelli, Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of α-galactosylceramides, Proc. Natl. Acad. Sci. U.S.A., 102: 3383–3388, 2005.
   PubMed Web of Science ®Google Scholar
• J. Schmieg, G. Yang, R.W. Franck, and M. Tsuji, Superior protection against malaria and melanoma metastases by a C-blycoside analogue of the natural killer T cell ligand α-galactosylceramide, J. Exp. Med., 198: 1631–1641, 2003.
   PubMed Web of Science ®Google Scholar
• L.M. Mars, V. Laloux, K. Goude, S. Desbois, A. Saoudi, L. Van Kaer, H. Lassmann, A. Herbelin, A. Lehuen, and R.S. Liblau, Vα14-Jα281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice, J. Immunol., 168: 6007–6011, 2002.
   PubMed Web of Science ®Google Scholar
• A. Teige, I. Teiga, S. Savasani, R. Bockermann, E. Mondoc, R. Holmdahl, and S. Issazadel-Navikas, CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis, J. Immunol., 172: 186–194 2004.
   PubMed Web of Science ®Google Scholar
• A.K. Singh, M.T. Wilson, S. Hong, D. Oliveres-Villagomez, C. Du, A.K. Stanic, S. Joyce, S. Siriam, Y. Koezka, and L. Van Kaer, Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis, J. Exp. Med., 194: 1801–1811, 2001.
   PubMed Web of Science ®Google Scholar
• R. Furlan, A. Bergami, D. Cantarella, E. Brambilla, M. Taniguchi, P. Dellabona, G. Casorati, and G. Martino, Activation of invariant NKT cells by αGalCer administration protects mice from MOG35–55-induced EAE: Critical roles for administration route and IFN-γ Eur. J. Immunol., 33: 1830–1838, 2003.
   PubMed Web of Science ®Google Scholar
• AW. Jahng, I. Maricic, B. Pedersen, N. Burdin, and O. Naidenko, Activatin of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis, J. Exp. Med., 194: 1789–1799, 2001.
   PubMed Web of Science ®Google Scholar
• J.M. Gombert, A. Herbelin, E. Tancrede-Bohin, M. Dy, C. Carnaud, and J.F. Bach, Early quantitative and functional deficiency of NK1 + -like thymocytes in the NOD mouse, Eur. J. Immunol., 26: 2989–2998, 1996.
   PubMed Web of Science ®Google Scholar
• M. Falcone, B. Yeung, L. Tucker, E. Rodriguez, and N. Sarvetnick, A defect in interleukin 12-induced activation and interferon gamma secretion of peripheral natural killer T cells in nonobese diabetic mice suggests new pathogenic mechanisms for insulin-dependent diabetes mellitus J. Exp. Med., 190: 963–972, 1999.
   PubMed Web of Science ®Google Scholar
• D.I. Godfrey, S.J. Kinder, P. Silvera, and A.G. Baxter, Flow cytometric study of T cell development in NOD mice reveals a deficiency in alpha-beta TCR + CDR-CD8-thymocytes, J. Autoimmun., 10: 279–285, 1997.
   PubMed Web of Science ®Google Scholar
• L.D. Poulton, M.J. Smyth, C.G. Hawke, P. Silveira, D. Shepherd, O.V. Naidenko, D.I. Godfrey, and A.G. Baxter, Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice, Int. Immunol., 13: 887–896, 2001.
   PubMedGoogle Scholar
• F.D. Shi, M. Flodstrom, B. Balasa, S.H. Kim, K. van Gunst, J.L. Strominger, S.B. Wilson, and N. Sarvetnick, Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse, Proc. Natl. Acad. Sci. U. S. A., 98: 6777–6782, 2001.
   PubMed Web of Science ®Google Scholar
• Y.N. Naumov, K.S. Bahjat, R. Gausling, R. Abraham, M.A. Exley, Y. Koezuka, S.B. Balk, J.L. Stominger, M. Clare-Salzer, and S.B. Wilson, Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets, Proc. Natl. Acad. Sci. U. S. A., 98: 13838–13843, 2001.
   PubMed Web of Science ®Google Scholar
• B. Wang, Y.-B. Geng, and C.-R. Wang, CD1-restrected NKT cells protect nonobese diabetic mice from developing diabetes, J. Exp. Med., 194: 313–320, 2001.
   PubMed Web of Science ®Google Scholar
• M. Falcone, F. Facciotti, N. Ghidoli, P. Monti, S. Olivieri, L. Zaccagnino, E. Bonifacio, G. Casorati, F. Sanvito, and N. Sarventrick, Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice, J. Immunol., 172: 5908–5916, 2004.
   PubMed Web of Science ®Google Scholar
• K.J.L. Hammond, L.D. Poulton, L.J. Almisano, P.A. Silveira, D.I. Godrey, and A.G. Bazter, α/β-T cell receptor (TCR)+ CD4−CD8− (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10, J. Exp. Med., 187: 1047–1056, 1998.
   PubMed Web of Science ®Google Scholar
• A. Lehuen, O. Lantz, L. Beaudoin, V. Laloux, C. Carnaud, A. Bendelac, J.-F. Bach, and R.C. Monteriro, Overexpression of natural killer T cells protects Vα14-Jα18 transgenic nonobese diabetic mice against diabetes, J. Exp. Med., 188: 1831–1839, 1998.
   PubMed Web of Science ®Google Scholar
• S. Hong, M.T. Wilson, I, Serizawa, L. Wu, N. Singh, O.V. Naidenko, T. Miura, T. Haba, D.C. Scherer, J. Wei, M. Kronenberg, Y. Koezuka, and L. Van Kaer, The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice, Nat. Med., 7: 1052–1056, 2001.
   PubMed Web of Science ®Google Scholar
• S. Sharif, G.A. Arreaza, P. Zucker, Q.-S. Mi, J. Sondhi, O.V. Naidenko, M. Kronenberg, Y. Koezuka, T.L. Delovitch, J.-M. Gombert, M. Leite-de-Moraes, C. Gouarin, R. Zhu, A. Hameg, T. Nakayama, M. Taniguchi, F. Lepault, A. Lehuen, J.-F. Bach, and A. Herbelin, Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes, Nat. Med., 7: 1057–1062, 2001.
   PubMed Web of Science ®Google Scholar
• M. Mizuno, M. Masumura, C. Tomi, A. Chiba, S. Oki, T. Yamamura, and S. Miyake, Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice, J. Autoimmun., 10: 279–285, 1997.
   Google Scholar
• V. Laloux, L. Beaudoin, D. Jeske, C. Carnaud, and A. Lehuen, NKT cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen, J. Immunol., 166: 3749–3756, 2001.
   PubMedGoogle Scholar
• L. Beaudoin, V. Laloux, J. Novak, B. Lucas, and A. Lehuen, NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells, Immunity, 17: 725–736, 2002.
   PubMed Web of Science ®Google Scholar
• J. Novak, L. Beaudoin, T. Griseri, and A. Lehuen, Inhibition of T cells differentiation into effectors by NKT cells requires cell contacts, J. Immunol., 174: 1954–1961, 2005.
   PubMed Web of Science ®Google Scholar
• Y.G. Chen, C.M. Choisy-Rossi, T.M. Holl, H.D. Champan, G.S. Besra, S.A. Porcelli, D.J. Shaffer, D. Roopenian, S.B. Wilson, and D.V. Serreze, Activated NKT cells inhibit autoimmune diabetes through tolerogenic recruitment of dendritic cells to pancreatic lymph nodes, J. Immunol., 174: 1196–1204, 2005.
   PubMed Web of Science ®Google Scholar
• A.S. Korganow, H. Ji, S. Mangialaio, V. Dchatelle, R. Pelanda, T. Martin, C. Degott, H. Kikutani, K. Rajewsky, J.L. Pasquali, C. Benoist, and D. Mathis, From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins, Immunity, 10: 451–461, 1999.
   PubMed Web of Science ®Google Scholar
• K. Terato, K.A. Hasty, R.A. Reife, M.A. Cremer, H. Kang, and J.M. Stuart, Induction of arthritis with monoclonal antibodies to collagen, J. Immunol., 148: 2103–2108, 1992.
   PubMed Web of Science ®Google Scholar
• J.Q. Yang, V. Saxena, H. Xu, L. van Kaer, C.-R. Wang, and R.R. Singh, Repeated α-galactosylceramide administration results in expansion of NKT cells and alleviates inflammatory dermatitis in MRL-lpr/lpr mice, J. Immunol., 171: 4439–4446, 2003.
   PubMed Web of Science ®Google Scholar
• O.T.M. Chan, V. Paliwal, J.M. Mcniff, S.H. Park, A. Bendelac, and M.J. Schlomchik, Deficiency in β2-microglobulin, but not CD1, accelerates spontaneous lupus skin disease while inhibiting nephritis in MRL-Faslpr mice: An example of disease regulation at the organ level, J. Immunol., 167: 2985–2990, 2001.
   PubMedGoogle Scholar
• J.-Q. Yang, V. Saxena, H. Xu, L. Van Kaer, C.-R. Wang, and R.R. Singh, Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis, J. Immunol., 171: 4439–4446, 2003.
   PubMed Web of Science ®Google Scholar
• A.K. Singh, J.Q. Yang, V.V. Parekh, J. Wei, C.R. Wang, S. Joyce, R.R. Singh, and L. van Kaer, The natural killer T cell ligand α-galactosylceramide prevents or promotes pristine-induced lupus in mice, Eur. J. Immunol., 35: 1143–1154, 2005.
   PubMed Web of Science ®Google Scholar
• S.R.M. Morshe, K. Mannoor, R.C. Halder, H. Kawamura, M. Bannai, H. Sekikawa, H. Watanabe, and T. Abo, Tissue-specific expansion of NTK and CD5+B cells at the onset of autoimmune disease in (NZB x NZW)F1 mice, Eur. J. Immunol., 32: 2551–2561, 2002.
   PubMedGoogle Scholar
• C. Firestier, A. Molano, J.S. Im, Y. Dutronc, B. Diamond, A. Davidson, P.A. Illarionov, G.S. Besra, and S.A. Porcelli, Expansion and hyperactivity of CD1d-restricted NKT cells during the progression of systemic lupus erythematosus in (New Zealand Black x New Zealand White) F1 mice, J. Immunol., 175: 763–770, 2005.
   Google Scholar
• D. Zeng, Y. Liu, S. Sidobre, M. Kronenberh, and S. Strober, Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus, J. Clin. Invest., 112: 1211–1222, 2003.
   PubMed Web of Science ®Google Scholar
• L.J. Saubermann, P. Beck, Y.P.D. Jong, R.S. Pitman, M.S. Ryan, H.S. Kim, M. Exley, S. Snapper, S.P. Balk, S.J. Hagen, O. Kanauchi, K. Motoki, T. Sakai, C. Terhorst, Y. Koezuka, D.K. Podolsky, and R.S. Blumerg, Activation o f natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice, Gastroenterology, 119: 119–128, 2000.
   PubMed Web of Science ®Google Scholar
• Y. Ueno, S. Tanaka, M. Sumi, S. Miyake, S. Tazuma, M. Taniguchi, T. Yamamura, and K. Chyayama, Single dose of OCH improges mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice, Inflamm. Bowel Dis., 11: 35–41, 2005.
   PubMedGoogle Scholar
• F. Heller, I.J. Fuss, E.E. Nieuwenhuis, R.S. Blumberg, and W. Strober, Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells, Immunity, 17: 629–38, 2002.
   PubMed Web of Science ®Google Scholar
• G. Giaccone, C.J. Punt, Y. Ando, T. Ruijter, N. Nishi, M. Peters, B.M. von Blomberg, R.J. Scheper, H.J. van der Vliet, A.J. van den Eertwegh, M. Roelvink, J. Beijnen, H. Zwierzina, and H.M. Pinedo, A phase I study of the natural killer T cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors, Clin. Cancer Res., 8: 3702–3709, 2002.
   PubMed Web of Science ®Google Scholar
• A. Ishikawa, S. Motohashi, E. Ishikawa, H. Fuchida, K. Higashino, M. Otsuji, T. Iizasa, T. Nakayama, M. Taniguchi, and T. Fujisawa, A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer, Clin. Cancer Res., 11: 1910–1917, 2005.
   PubMed Web of Science ®Google Scholar
• V.V. Parekh, M.T. Wilson, D. Olivares-Villagomez, A.K. Singh, L. Wu, C.R. Wang, S. Joyce, and L. Van Kaer, Glycolipid antigen induces long-term natural killer T cell anergy in mice, J. Clin. Invest., 115: 2572–2583, 2005.
   PubMed Web of Science ®Google Scholar